(Q56880573)

English

Building on the past to define an efficient path to an HIV vaccine

article

In more languages

edit

Statements

0 references

0 references

Building on the past to define an efficient path to an HIV vaccine (English)

0 references

Bette Korber

1

0 references

publication date

July 2011

0 references

published in

Expert Review of Vaccines

0 references

volume

10

0 references

issue

7

0 references

page(s)

929-931

0 references

cites work

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Post-step modifications for research on HIV vaccines

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

HIV-1 vaccine development after STEP.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1586%2FERV.11.81

retrieved

21 January 2018

Identifiers

DOI

10.1586/ERV.11.81

0 references

PubMed publication ID

21806390

0 references

(Q56880573)

Building on the past to define an efficient path to an HIV vaccine

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)